title: Can two be better than one? Dual RAS blockade in patients with type 2 diabetes and overt nephropathy in the age of ONTARGET and ALTITUDE.
authors.affiliation: Division of Endocrinology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; Dr.
authors.forename: Julie A
authors.initials: JA
authors.lastname: Lovshin
authors.affiliation: Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
authors.forename: David Zev Lssac
authors.initials: DZ
authors.lastname: Cherney
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D012084:Renin-Angiotensin System / Q000187:drug effects*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents